Search and analyze individual stocks with comprehensive metrics

Trident Lifeline

TLLPharmaceuticals & Biotechnology

Fundamental Score

...

Trident Lifeline Share Price & Market Analysis

Current Market Price (CMP)
290.25
No change data available
Market Cap
336.46 (Cr)
Industry
Pharmaceuticals & Biotechnology

Profitability Metrics

Excellent

Return on Equity

20.02%
Good

Return on Capital Employed

17.97%

Operating Profit Margin (5Y)

N/A
Poor

Dividend Yield

0.00%

Valuation Metrics

Excellent

Price to Earnings

21.02x

Market Capitalization

336.46 (Cr)

Industry P/E

33.97x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

33.62%
Excellent

YoY Quarterly Sales Growth

79.54%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

0.84x
Excellent

Interest Coverage

5.68x

Free Cash Flow (5Y)

N/A

Ownership Structure

Good

Promoter Holding

63.04%
Average

FII Holding

7.21%
Poor

DII Holding

0.39%
Good

Pledged Percentage

3.46%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
63.04%
Promoter Holding
336.46 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of TLL across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Return on Equity (20.02%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (17.97%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Attractive Valuation (P/E: 21.02 vs Industry: 33.97)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.

Robust Profit Growth (33.62%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (79.54%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Strong Interest Coverage (5.68x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (63.04%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Risk Factors

3 factors identified

Limited Institutional Interest (FII+DII: 7.60%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

📊 Educational Market Overview

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Trident Lifeline

About TLL

Company Details

Symbol:TLL
Industry:Pharmaceuticals & Biotechnology
Sector:Pharmaceuticals

Market Information

Market Cap:336.46 (Cr)
P/E Ratio:21.02
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.00%

TLL Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)20.02%
Return on Capital Employed17.97%
Operating Profit Margin (5Y)N/A%
Debt to Equity Ratio0.84
Interest Coverage Ratio5.68

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth33.62%
YoY Quarterly Sales Growth79.54%

Frequently Asked Questions

What is the current price of TLL?

TLL is currently trading at ₹290.25 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of TLL shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of TLL and what does it mean?

TLL has a P/E ratio of 21.02x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.

How is TLL performing according to Bull Run's analysis?

TLL has a Bull Run fundamental score of 43.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 20.02%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does TLL belong to?

TLL operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Trident Lifeline. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for TLL?

TLL has an ROE of 20.02%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Trident Lifeline generates profits from shareholders' equity. An ROE of 20% means the company generates ₹20 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is TLL's debt-to-equity ratio and what does it indicate?

TLL has a debt-to-equity ratio of 0.84, which indicates moderate leverage that should be monitored. This means the company has ₹84 of debt for every ₹100 of equity. Higher leverage can amplify returns during good times but increases bankruptcy risk during downturns.

What is TLL's dividend yield and is it a good dividend stock?

TLL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has TLL grown over the past 5 years?

TLL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in TLL and why does it matter?

Promoters hold 63.04% of TLL shares, with 3.46% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does TLL compare with its industry peers?

TLL trades at P/E 21.02x vs industry average 33.97x, with ROE of 20.02% and ROCE of 17.97%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether TLL is outperforming its competitive set in profitability, growth, and valuation metrics.

What is TLL's market capitalization and what category does it fall into?

TLL has a market capitalization of ₹336 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for TLL?

Key ratios for TLL: ROE 20.02% (Excellent), ROCE 17.97%, P/E 21.02x, Debt-to-Equity 0.84, Interest Coverage 5.68x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is TLL stock and what is its beta?

TLL has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for TLL?

TLL has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹290.25, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in TLL?

Key risks for TLL include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.84), and operational challenges. The stock has a Fundamental Score of 43.9/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is TLL's operating profit margin and how has it trended?

TLL has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.

How is TLL's quarterly performance in terms of sales and profit growth?

TLL's recent quarterly performance shows YoY Sales Growth of 79.54% and YoY Profit Growth of 33.62%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in TLL?

TLL has FII holding of 7.21% and DII holding of 0.39%, totaling 7.60% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.